DiviTum® TKa results to be presented at ASCO

2023-06-01 16:02

Biovica, active in cancer diagnostics, today announces that a poster with DiviTum® TKa results from the SWOG study S0226 will be presented at the the world’s largest cancer conference, the annual ASCO meeting, on Sunday, June 4. The data supports the use of DiviTum TKa as a unique biomarker test that provides important clinical information about HR+ metastatic breast cancer (MBC) status.

The study compares results from the DiviTum TKa test and CA 15-3, a biomarker test currently used routinely when treating MBC. The study investigators conclude that:

  • Baseline (BL) DiviTum TKa values are highly prognostic in patients with HR+ MBC initiating first line systemic Endocrine Therapy (low BL TKa = superior prognosis)
  • Baseline CA 15-3 is not prognostic at baseline but after 3 cycles of treatment
  • High baseline TKa and high baseline CA 15-3 confer inferior prognosis
  • DiviTum TKa and CA 15-3 are complimentary biomarkers and can provide a more complete picture of disease status.

“The results confirm DiviTum TKa’s ability to monitor and predict outcome in HR+ MBC, enabling more informed treatment decisions. It is very gratifying that DiviTum TKa can complement and improve today's standard methods of breast cancer monitoring, for the benefit of patients and for increased clinical use of DiviTum TKa,” said Anders Rylander, CEO Biovica.

Link to study: https://meetings.asco.org/abstracts-presentations/222604
Ref. E Cobain et al, J Clin Oncol 41, 2023 (suppl 16; abstr 1076)

>4,500

Numbers of patients in studies

28

Publications

18

Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program

No